An initiative of Flandersbio

Listed companies

Listed companies

in english

The combined market cap of Belgian SME biotech companies gained top position in the European ranking. The fact that the number of qualifying companies is 2 to 3 times smaller than in other European countries confirms the intrinsic quality of the Belgian public biotech sector.

Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease.

Ablynx on FlandersBio.be

 

Chart IPO Statistics Pipeline Contact

Click on the chart to follow the daily exchange rate.

View the NYSE Euronext chart

  • Listing date:   07/11/2007

View chart De Tijd

Product Indications and progress Partner
Caplacizumab Haematology
 
Ozoralizumab Inflammation/Immunology Eddingpharm in Greater China
 
Ozoralizumab Inflammation/Immunology Taisho in Japan
 
Vobarilizumab Inflammation/Immunology Abbvie
 
ALX-0141 (RANKL) Musculoskeletal Eddingpharm in Greater China
 
ALX-0171 (RSV) Pulmonary disease
 
ALX-0761 Inflammation/Immunology Merck Serono
 
Various Internal and fully partnered Boehringer Ingelheim, Merck Serono, Novartis, and Merck & Co.
 

Investor Relations:
Marieke Vermeersch, Director IR & Corporate Communications
Email:
Phone: +32 (0)9 262 00 82

Address details:
Bio-accelerator, Technologiepark 21, 9052 Ghent, Belgium
Website: http://www.ablynx.com
Email:

Back to top

Print